title: Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) Is a Novel Nutritional Therapeutic Target for Hyperlipidemia, Non-Alcoholic Fatty Liver Disease, and Atherosclerosis.
abstract: Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor family and has a unique structure, which facilitates its multiple functions as a co-receptor for Wnt/β-catenin signaling and as a ligand receptor for endocytosis. The role LRP6 plays in metabolic regulation, specifically in the nutrient-sensing pathway, has recently garnered considerable interest. Patients carrying an LRP6 mutation exhibit elevated levels of LDL cholesterol, triglycerides, and fasting glucose, which cooperatively constitute the risk factors of metabolic syndrome and atherosclerosis. Since the discovery of this mutation, the general role of LRP6 in lipid homeostasis, glucose metabolism, and atherosclerosis has been thoroughly researched. These studies have demonstrated that LRP6 plays a role in LDL receptor-mediated LDL uptake. In addition, when the LRP6 mutant impaired Wnt-LRP6 signaling, hyperlipidemia, non-alcoholic fatty liver disease, and atherosclerosis developed. LRP6 regulates lipid homeostasis and body fat mass via the nutrient-sensing mechanistic target of the rapamycin (mTOR) pathway. Furthermore, the mutant LRP6 triggers atherosclerosis by activating platelet-derived growth factor (PDGF)-dependent vascular smooth muscle cell differentiation. This review highlights the exceptional opportunities to study the pathophysiologic contributions of LRP6 to metabolic syndrome and cardiovascular diseases, which implicate LRP6 as a latent regulator of lipid metabolism and a novel therapeutic target for nutritional intervention.
authors.affiliation: Department of Food and Nutrition, Kookmin University, Seoul 136-702, Korea. gwgo@kookmin.ac.kr.
authors.forename: Gwang-woong
authors.initials: GW
authors.lastname: Go
mesh_terms: D000818:Animals; D050197:Atherosclerosis / Q000178:diet therapy / Q000235:genetics*; D008078:Cholesterol, LDL / Q000097:blood; D004195:Disease Models, Animal; D018390:Gene Targeting / Q000379:methods*; D006706:Homeostasis; D006801:Humans; D006949:Hyperlipidemias / Q000178:diet therapy / Q000235:genetics*; D050356:Lipid Metabolism / Q000235:genetics; D060488:Low Density Lipoprotein Receptor-Related Protein-6 / Q000235:genetics / Q000378:metabolism*; D065626:Non-alcoholic Fatty Liver Disease / Q000178:diet therapy / Q000235:genetics*; D011973:Receptors, LDL / Q000235:genetics / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases / Q000235:genetics / Q000378:metabolism; D014280:Triglycerides / Q000097:blood; D060449:Wnt Signaling Pathway; D051176:beta Catenin / Q000235:genetics / Q000378:metabolism
chemical_list: D008078:Cholesterol, LDL; C555475:LRP6 protein, human; D060488:Low Density Lipoprotein Receptor-Related Protein-6; D011973:Receptors, LDL; D014280:Triglycerides; D051176:beta Catenin; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases
keywords: LRP6; atherosclerosis; dyslipidemia; non-alcoholic fatty liver disease